Healthcare · Biotechnology
Price
$31.47
Market Cap
$3.9B
Employees
155
Beta
1.19
Avg Volume
3,864,396
CEO
Malte Peters
Business Description
Tango Therapeutics, Inc. is a biotechnology firm dedicated to the research and development of innovative cancer treatments. Their primary therapeutic candidate, TNG908, is a synthetic lethal small molecule designed to inhibit protein arginine methyltransferase 5 (PRMT5). This compound is currently being advanced as a potential therapy for cancers characterized by methylthioadenosine phosphorylase (MTAP) deletions. Additionally, their pipeline includes an Ubiquitin-specific protease 1 (USP1) inhibitor targeting BRCA1 or BRCA2-mutant cancers, and a program known as 'Target 3' which addresses STK11-mutant cancers. Tango Therapeutics maintains a strategic alliance with Gilead Sciences, Inc., focused on the identification, advancement, and commercialization of a diverse array of cancer therapies. Established in 2017, the company's operations are headquartered in Cambridge, Massachusetts.
Business History
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-36.17
Stock Price: $31.47
EPS (Diluted): -0.87
EPS (Diluted): -0.87
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
2.97
Stock Price: $31.47
Total Equity: $346.18M
Shares: 116,166,187
Total Equity: $346.18M
Shares: 116,166,187
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-36.06
Market Cap: $3.92B
Total Debt: $30.83M
Cash: $112.28M
EBITDA: -$99.31M
Total Debt: $30.83M
Cash: $112.28M
EBITDA: -$99.31M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$950.5M
Market Cap: $3.92B
Total Debt: $30.83M
Cash: $112.28M
Total Debt: $30.83M
Cash: $112.28M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
16.50
Stock Price: $31.47
Revenue: $62.38M
Shares: 116,166,187
Revenue: $62.38M
Shares: 116,166,187
EV/Sales (Total value vs revenue — works when P/E can't)
API15.24
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
96.3%
Gross Profit: $60.10M
Revenue: $62.38M
Revenue: $62.38M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-178.4%
Operating Income: -$111.29M
Revenue: $62.38M
Revenue: $62.38M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-162.9%
Net Income: -$101.59M
Revenue: $62.38M
Revenue: $62.38M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-41.5%
Net Income: -$101.59M
Total Equity: $346.18M
Total Equity: $346.18M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-27.7%
Operating Income: -$111.29M
Tax Rate: 0.0%
Equity: $346.18M
Total Debt: $30.83M
Cash: $112.28M
Tax Rate: 0.0%
Equity: $346.18M
Total Debt: $30.83M
Cash: $112.28M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
16.32
Current Assets: $353.76M
Current Liabilities: $21.68M
Current Liabilities: $21.68M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.09
Short-Term Debt: $0.00
Long-Term Debt: $30.83M
Total Debt: $30.83M
Total Equity: $346.18M
Long-Term Debt: $30.83M
Total Debt: $30.83M
Total Equity: $346.18M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$0.54
Revenue: $62.38M
Shares: 116,166,187
Shares: 116,166,187
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$2.98
Total Equity: $346.18M
Shares: 116,166,187
Shares: 116,166,187
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-1.20
Operating CF: -$138.89M
CapEx: -$1.05M
Shares: 116,166,187
CapEx: -$1.05M
Shares: 116,166,187
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $31.47
Stock Price: $31.47
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$101.59M
Net Income: -$101.59M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares TNGX against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 26, 2026 11:00pm (11h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $37.0M | $24.9M | $36.5M | $42.1M | $62.4M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $2.3M |
| Gross Profit | $37.0M | $24.9M | $36.5M | $42.1M | $60.1M |
| Operating Expenses | $95.2M | $135.9M | $150.7M | $187.7M | $171.4M |
| Operating Income | -$58.2M | -$111.1M | -$114.2M | -$145.6M | -$111.3M |
| Net Income | -$58.2M | -$108.2M | -$101.7M | -$130.3M | -$101.6M |
| EBITDA | -$57.0M | -$106.5M | -$99.2M | -$127.6M | -$99.3M |
| EPS | $-0.94 | $-1.23 | $-1.08 | $-1.19 | $-0.87 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 26, 2026 11:00pm (11h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $142.7M | $60.0M | $66.4M | $69.5M | $112.3M |
| Total Current Assets | $492.3M | $375.3M | $346.5M | $266.3M | $353.8M |
| Total Assets | $500.2M | $436.5M | $402.6M | $316.5M | $398.7M |
| Current Liabilities | $40.7M | $55.5M | $45.9M | $38.2M | $21.7M |
| Long-Term Debt | $0 | $0 | $0 | $0 | $30.8M |
| Total Liabilities | $155.4M | $187.0M | $149.5M | $117.0M | $52.5M |
| Total Equity | $344.7M | $249.5M | $253.1M | $199.5M | $346.2M |
| Retained Earnings | -$161.3M | -$269.5M | -$371.3M | -$501.6M | -$603.2M |
Cash Flow (Annual)
Last updated: Jun 26, 2026 11:00pm (11h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$59.5M | -$109.1M | -$118.0M | -$131.5M | -$138.9M |
| Capital Expenditure | -$1.8M | -$7.7M | -$1.5M | $-754,000 | -$1.0M |
| Free Cash Flow | -$61.4M | -$116.8M | -$119.5M | -$132.3M | -$139.9M |
| Acquisitions (net) | $0 | $0 | $0 | $0 | $0 |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | $114.4M | -$81.1M | $5.9M | $2.3M | $42.7M |
Analyst Estimates (Annual)
Last updated: Jun 26, 2026 11:00pm (11h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$3.9M $3.9M – $3.9M
|
$63.7M $63.7M – $63.7M
|
$255.9M $255.9M – $255.9M
|
$658.7M $658.7M – $658.7M
|
| EBITDA |
-$3.9M -$3.9M – -$3.9M
|
-$63.7M -$63.7M – -$63.7M
|
-$255.9M -$255.9M – -$255.9M
|
-$658.7M -$658.7M – -$658.7M
|
| Net Income |
-$171.6M -$205.2M – -$138.0M
|
-$173.1M -$219.6M – -$126.6M
|
-$110.5M -$110.5M – -$110.5M
|
$102.9M $102.9M – $102.9M
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 26, 2026 11:00pm (11h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -32.9% | +46.9% | +15.2% | +48.3% |
| Gross Profit Growth | -32.9% | +46.9% | +15.2% | +42.9% |
| Operating Income Growth | -90.9% | -2.8% | -27.5% | +23.6% |
| Net Income Growth | -85.8% | +5.9% | -28.1% | +22.0% |
| EBITDA Growth | -86.7% | +6.9% | -28.6% | +22.2% |
Insider Trading (Recent)
Last updated: Jun 27, 2026 6:32am (3h ago)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2026-06-19 | Azelby Robert | A-Award | 35,910.00 | $27.97 | $1.0M |
| 2026-06-19 | Azelby Robert | A-Award | 5,740.00 | $0.00 | $0 |
| 2026-06-19 | Azelby Robert | 0.00 | $0.00 | $0 | |
| 2026-06-05 | Ketchum John B | A-Award | 25,000.00 | $20.22 | $505,500 |
| 2026-06-05 | Ketchum John B | A-Award | 4,000.00 | $0.00 | $0 |
| 2026-06-05 | Calhoun Lesley Ann | A-Award | 25,000.00 | $20.22 | $505,500 |
| 2026-06-05 | Calhoun Lesley Ann | A-Award | 4,000.00 | $0.00 | $0 |
| 2026-06-05 | Rothenberg Mace | A-Award | 4,000.00 | $0.00 | $0 |
| 2026-06-05 | Rothenberg Mace | A-Award | 25,000.00 | $20.22 | $505,500 |
| 2026-06-05 | Lee Sung | A-Award | 570.00 | $0.00 | $0 |
| 2026-06-05 | Lee Sung | A-Award | 3,570.00 | $20.22 | $72,185 |
| 2026-06-01 | Crystal Adam | M-Exempt | 27,000.00 | $5.20 | $140,400 |
| 2026-06-01 | Crystal Adam | M-Exempt | 27,000.00 | $5.20 | $140,400 |
| 2026-06-01 | Crystal Adam | S-Sale | 6,140.00 | $22.25 | $136,627 |
| 2026-06-01 | Crystal Adam | S-Sale | 20,860.00 | $23.06 | $480,944 |
| 2026-05-01 | Crystal Adam | M-Exempt | 27,000.00 | $5.20 | $140,400 |
| 2026-05-01 | Crystal Adam | M-Exempt | 27,000.00 | $5.20 | $140,400 |
| 2026-05-01 | Crystal Adam | S-Sale | 25,900.00 | $21.19 | $548,901 |
| 2026-05-01 | Crystal Adam | S-Sale | 1,100.00 | $22.00 | $24,196 |
| 2026-05-01 | Gall Matthew | A-Award | 240,000.00 | $20.98 | $5.0M |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for TNGX — it's generated by the pipeline (
market-narrative step).
No community reviews yet for TNGX.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30